Asenapine: preclinical evidence for clinical effects in Schizophrenia

被引：0
|
作者：
Franberg, O.
Marcus, M. M.
Konradsson, A.
Jardemark, K.
Schilstrom, B.
Wiker, C.
Shahid, M.
Wong, E. H. F.
Svensson, T. H.
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Organon Lab Ltd, Newhouse Lanarkshire, England
[3] Pfizer Global R&D, Ann Arbor, MI USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2007年 / 17卷
关键词：
D O I：
10.1016/S0924-977X(07)70024-X
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S20 / S21
页数：2
相关论文
共 50 条
  • [1] Asenapine:: Preclinical evidence for clinical effects in schizophrenia
    Marcus, Monica M.
    Franberg, Olivia
    Konradsson, Asa
    Jardemark, Kent
    Schilstrom, Bjorn
    Wiker, Charlotte
    Shahid, Mohammed
    Wong, Erik H.
    Svensson, Torgny H.
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S239 - S240
  • [2] Asenapine:: preclinical evidence for clinical effects in schizophrenia and cognitive dysfunction
    Svensson, T. H.
    Frånberg, O.
    Konradsson, A.
    Jardemark, K.
    Schilstroem, B.
    Wiker, C.
    Ivanov, V.
    Shahid, M.
    Wong, E. H. F.
    Marcus, M. M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S477 - S477
  • [3] Asenapine: Preclinical evidence for clinical effects in schizophrenia and cognitive dysfunction
    Franberg, O.
    Marcus, M. M.
    Wiker, C.
    Konradsson, A.
    Schilstrom, B.
    Ivanov, V.
    Shahid, M.
    Wong, E. H.
    Svensson, T. H.
    NORDIC JOURNAL OF PSYCHIATRY, 2007, 61 (06) : 497 - 497
  • [4] Asenapine:: Preclinical evidence for clinical effects in schizophrenia and cognitive dysfunction
    Svensson, T. H.
    Franberg, O.
    Konradsson
    Jardemark, K.
    Schilstrom, B.
    Wiker, C.
    Ivanov, V.
    Shahid, M.
    Wong, E. H.
    Marcus, M. M.
    SCHIZOPHRENIA BULLETIN, 2007, 33 (02) : 324 - 324
  • [5] Asenapine, a novel psychopharmacological agent:: Preclinical evidence for clinical effects in schizophrenia
    Oggesjo, O.
    Marcus, M. M.
    Konradsson, A.
    Jardemark, K.
    Schilstrom, B.
    Wiker, C.
    Shahid, M.
    Wong, E. H. F.
    Svensson, T. H.
    NORDIC JOURNAL OF PSYCHIATRY, 2006, 60 (04) : 339 - 339
  • [6] Asenapine, a novel psychopharmacologic agent:: preclinical evidence for clinical effects in schizophrenia
    Franberg, Olivia
    Wiker, Charlotte
    Marcus, Monica M.
    Konradsson, Asa
    Jardemark, Kent
    Schilstrom, Bjorn
    Shahid, Mohammed
    Wong, Erik H. F.
    Svensson, Torgny H.
    PSYCHOPHARMACOLOGY, 2008, 196 (03) : 417 - 429
  • [7] Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia
    Olivia Frånberg
    Charlotte Wiker
    Monica M. Marcus
    Åsa Konradsson
    Kent Jardemark
    Björn Schilström
    Mohammed Shahid
    Erik H. F. Wong
    Torgny H. Svensson
    Psychopharmacology, 2008, 196 : 417 - 429
  • [8] The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania
    Tarazi, Frank I.
    Neill, Jo C.
    EXPERT OPINION ON DRUG DISCOVERY, 2013, 8 (01) : 93 - 103
  • [9] Evaluation of the clinical efficacy of asenapine in schizophrenia
    Minassian, Arpi
    Young, Jared W.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (12) : 2107 - 2115
  • [10] Management of schizophrenia: clinical experience with asenapine
    Cortese, Leonardo
    Bressan, Rodrigo A.
    Castle, David J.
    Mosolov, Sergey N.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2013, 27 (S4) : 14 - 22
12345